$IRD News

RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares

Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate

Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease

TD Cowen Initiates Coverage On Opus Genetics with Buy Rating

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026

BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29

Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13

HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases - Slideshow

Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target

Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target